Cognivo Bridge turns a 3-minute smartphone recording into continuous neurodegenerative disease monitoring - delivered to your nurse portal every day. No wearables. No clinic visit required.
The patient records at home. Our AI extracts the biomarkers. You get a clinical PDF report. It takes under 3 minutes.
Three quick voice tasks on their smartphone: a sustained vowel, a rapid syllable task, and reading a short passage aloud.
→The app verifies audio quality in real time and prompts a retry if the recording doesn't meet clinical standards.
→Our scoring engine extracts clinically validated acoustic biomarkers and computes clinical scores within seconds.
→A 2-page PDF clinical report with biomarker trends, triage status, and clinical interpretation lands in your nurse portal.
Each task targets a different dimension of neuromotor speech function. Our AI extracts clinically validated biomarkers and delivers trend analysis to your nurse portal.
The patient holds a steady vowel sound. This isolates vocal fold vibration - the gold standard task in voice laboratories worldwide. Any instability comes directly from the neuromuscular control of the larynx.
Vocal fold stability, tremor detection and classification, voice quality trends over time. Catches early signs of bulbar involvement before they're audible in conversation.
This rapid syllable task exercises the full oral-motor system. When neuromotor pathways degrade, it shows up as measurable changes in speed and regularity that are difficult to detect by ear.
Oral motor speed and regularity, dysarthria classification, and medication response patterns. Compare morning vs. evening performance to quantify treatment effectiveness objectively.
The patient reads a standardized passage aloud. Unlike the first two tasks, reading loads the full system: respiration, phonation, articulation, and cognitive-linguistic processing simultaneously. This reveals deficits that simpler tasks cannot detect.
Connected speech analysis distinguishes between motor-dominant and cognitive-dominant impairment - guiding whether to adjust motor medications or screen for cognitive decline.
The broadest neurodegenerative disease coverage of any voice biomarker platform in neurology. Continuous monitoring between clinic visits.
Continuous motor monitoring, tremor tracking, and medication response assessment between clinic visits
Vocal tremor severity tracking and differentiation from other movement disorders
Speech coordination monitoring and motor pattern analysis for disease progression tracking
Cognitive-linguistic decline detection through connected speech analysis
Bulbar function tracking and longitudinal speech-motor decline measurement
Relapse detection and fatigue-related speech pattern monitoring
Treatment response tracking and voice quality monitoring over time
Speech pattern irregularity monitoring for disease progression assessment
Combined motor and cognitive speech decline monitoring
Every session is automatically classified based on the patient's biomarker trajectory relative to their personal baseline.
Building personal baseline (first 7 sessions). No alerts - data collection phase.
All biomarkers within personal baseline. Continue monitoring. Next scheduled visit.
Emerging deviation from baseline. Review PDF report. Schedule review within 2 weeks.
Sustained multi-zone decline. Motor, cognitive, or global. Urgent clinical review.
Cognivo Bridge sessions qualify for CMS Remote Therapeutic Monitoring (RTM) reimbursement, generating new monthly recurring revenue for every enrolled patient.
Three clinically validated voice tasks targeting motor, vocal fold, and cognitive-linguistic function in a single session.
Every session is classified against the patient's personal baseline. Your team sees who needs attention without reviewing every recording.
Purpose-built clinical dashboard with triage queue, biomarker trends, and downloadable PDF reports for every patient.
CMS-reimbursable Remote Therapeutic Monitoring built into the platform. New recurring revenue for your practice.
Cognivo Bridge addresses a large and growing market in vocal biomarker-based neurological monitoring. Purpose-built for the practicing neurologist - not for pharma trials, not for enterprise wellness.
CMS-reimbursable recurring revenue model. Clinical advisor network in place. Pilot-ready platform with the broadest neurodegenerative disease coverage of any voice biomarker solution.
Request Investor Materials →Detailed market sizing, unit economics, and clinical validation data available under NDA.
"Our mission transcends technology. We're building bridges between human potential and artificial intelligence, creating pathways for cognitive healing that honor both the complexity of the brain and the dignity of the human spirit."
Cognivo Manora Inc. is headquartered in the San Francisco Bay Area, California. We are building Cognivo Bridge - a voice biomarker platform purpose-built for the practicing neurologist who needs continuous, objective monitoring of their neurodegenerative disease patients between clinic visits.
Request a personalized demo and we'll walk you through the full platform - from patient recording to nurse portal to clinical PDF report.